Communication To Health Care Professionals Archives

27 Mar Levetiracetam – Risk of Drug Reaction With Eosinophilia and Systemic Symptoms (Dress)

Posted at 08:55h in

The following pharmaceutical companies, GlaxoSmithKline (GSK) South Africa, Ranbaxy Pharmaceuticals (Pty) Ltd South Africa, Pharma Dynamics (Pty) Ltd, Unicorn Pharmaceuticals (Pty) Ltd, Cipla Medpro (Pty) Ltd, Hetero Drugs South Africa (Pty) Ltd, Dr Reddy’s Laboratories (Pty) Ltd, in collaboration with the South African Health Products...

27 Mar Clobazam – Risk of Drug Reaction With Eosinophilia and Systemic Symptoms (Dress)

Posted at 08:53h in

The following pharmaceutical companies, Equity Pharmaceuticals (Pty) Ltd, Pharmacare Ltd t/a Aspen Pharmacare and Adcock Ingram Limited in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to inform you about the potential risk of drug reaction with eosinophilia and systemic symptoms...

15 Oct Corenza-c® Effervescent Tablets (C661 (Act 101/1965)): Amendment to Product Labelling – Not to Be Used in Children Under 12 Years of Age

Posted at 11:05h in

Adcock Ingram Limited, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the amended product labelling for Corenza-C® Effervescent Tablets to align with the recommended contraindicated use of aspirin in children under the age of 12 years...

03 Oct Valproate-containing Medicines – Potential Risk of Neurodevelopmental Disorders in Offspring of Fathers Treated With Valproate in the Three Months Prior to Conception

Posted at 10:31h in

The document is a Dear Healthcare Professional (DHCP) letter informing healthcare professionals about the risk of neurodevelopment disorders in children born to fathers exposed valproate valproate-containing medicines three months before conception....

11 Jun Pseudoephedrine-containing medicines – Risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)

Posted at 14:46h in

Haleon South Africa (SA), in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to inform you about the risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with the use of pseudoephedrine-containing medicines....

23 May Anviro® (Valaciclovir – Containing Medicine)– Risk of Drug Reaction With Eosinophilia and Systemic Symptoms (Dress)

Posted at 10:29h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Zydus would like to inform you about the risk of drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of Anviro® (valaciclovir) tablets....

30 Apr Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation

Posted at 14:04h in

Key Oncologies (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA), wish to inform you about the risk of thrombosis, including cerebral infarction, upon abrupt treatment discontinuation of anagrelide hydrochloride....

30 Apr Topical Corticosteroids – Risk of Withdrawal Reactions

Posted at 14:02h in

Organon South Africa (Pty) Ltd, as directed by the South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the risk of withdrawal reactions associated with inappropriate and long-term use of topical corticosteroids....

09 Apr Pseudoephedrine-containing medicines – Risks of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS) – Reckit

Posted at 14:29h in

Reckitt Benckiser Pharmaceuticals (Pty) Ltd in collaboration with the South African Health Products Regulatory Authority (SAHPRA), wish to draw your attention to the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome associated with the use of pseudoephedrine-containing medicines....

09 Apr Pseudoephedrine-containing Medicines Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS) – J&J

Posted at 09:03h in

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Johnson and Johnson (Pty) Ltd would like to inform you about the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with the use of pseudoephedrine-containing medicines....

Archive